An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985

• Published in: The American journal of cardiology Vol. 68; no. 10; pp. 1025 - 1031
• Main Authors: Hallstrom, Alfred P., Cobb, Leonard A., Yu, Ben Hui, Weaver, W.Douglas, Fahrenbruch, Carol E.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 15.10.1991; Elsevier
• Subjects: Anti-Arrhythmia Agents - therapeutic use; Antiarythmic agents; Biological and medical sciences; Cardiopulmonary Resuscitation; Cardiovascular system; Death, Sudden, Cardiac - prevention & control; Heart Arrest - prevention & control; Heart Arrest - therapy; Humans; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Procainamide - therapeutic use; Quinidine - therapeutic use; Recurrence; Risk Factors; Ventricular Fibrillation - prevention & control; Human; Intensive cardiocirculatory care; Cardiocirculatory arrest; Chemotherapy; Treatment; Arrhythmia; Cardiovascular disease; Ambulatory; Antiarrhythmia agent; Ventricular fibrillation
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/0002-9149(91)90490-C

Survival rates and antiarrhythmic drug use were determined in 941 consecutive patients resuscitated from prehospital cardiac arrest due to ventricular fibrillation between March 7, 1970, and March 6, 1985. Of these patients, 18.7% were treated for at least a portion of the period with quinidine, 17.5% with procainamide, and 39.4% received no antiarrhythmic agent. Beta blockers were prescribed for 28.3% of the patients. Unadjusted comparisons of survival estimates showed dramatically lower survival rates for patients who received antiarrhythmic drugs independent of β-blocker therapy and significantly improved survival for patients receiving β-blocker therapy independent of antiarrhythmic use. Patients for whom antiarrhythmic therapy was prescribed also had more adverse baseline risk factors, whereas patients taking β blockers had fewer such risk factors. After adjustment for these baseline risk factors, the use of antiarrhythmics was weakly (p < 0.09) associated with worsened survival; 2-year survival for procainamide-treated patients was 30% and quinidine-treated patients 55% (p = 0.003). Beta-blocker therapy was associated with improved (p < 0.001) survival. Thus, although neither procainamide nor quinidine appear to have had a benefit on mortality, the effect of procainamide appears to be significantly worse than that of quinidine. The use of antiarrhythmic drug therapy in patients resuscitated from prehospital ventricular fibrillation should be regarded as not only unproved, but potentially hazardous, and should probably be restricted to testing in randomized clinical trials.